02 July 2026
02 July 2026
Article doesn't exist
The lead product on AlzeCure’s platform has already demonstrated positive Phase I results.
Children as young as two with either sickle cell disease or thalassemia are now eligible for the gene therapy.
The real-world data study tracked Parkinson's disease patients for 12 months during treatment with AbbVie's Vyalev
Divarasib outperformed existing therapies in patients with KRAS G12C non-small cell lung cancer (NSCLC).
Namodenoson showed a tolerable safety profile consistent with previous studies.
Additional data on fall reduction could help give NeuroDerm's Onerji a competitive edge.
Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
